SCP Stock Overview
A clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Scancell Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.13 |
| 52 Week High | UK£0.23 |
| 52 Week Low | UK£0.071 |
| Beta | 0.45 |
| 11 Month Change | -0.76% |
| 3 Month Change | -34.17% |
| 1 Year Change | 16.96% |
| 33 Year Change | -44.49% |
| 5 Year Change | 197.73% |
| Change since IPO | -66.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| SCP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.6% | -0.009% | -1.2% |
| 1Y | 17.0% | -17.6% | 9.0% |
Return vs Industry: SCP exceeded the German Biotechs industry which returned -17.1% over the past year.
Return vs Market: SCP exceeded the German Market which returned 13.5% over the past year.
Price Volatility
| SCP volatility | |
|---|---|
| SCP Average Weekly Movement | 18.1% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SCP's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: SCP's weekly volatility has decreased from 25% to 18% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 61 | Linda Durrant | www.scancell.co.uk |
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, melanoma, ovarian, lung, and pancreatic cancers; and Modi-2, which targets homocitrullinated cancer antigens.
Scancell Holdings plc Fundamentals Summary
| SCP fundamental statistics | |
|---|---|
| Market cap | €156.23m |
| Earnings (TTM) | -€7.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-22.2x
P/E RatioIs SCP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCP income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£5.86m |
| Earnings | -UK£5.86m |
Last Reported Earnings
Apr 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0063 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -541.3% |
How did SCP perform over the long term?
See historical performance and comparison